Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01420627 · ClinicalTrials.gov registry record · Phase 3
EZN-2279 in Patients With ADA-SCID
A Phase 3 study, sponsored by Leadiant Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT01420627 is a Phase 3 study that has completed, run by Leadiant Biosciences. The registered enrollment target is 7 participants.
The verdict
NCT01420627, a Phase 3 study, has completed, sponsored by Leadiant Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.
Interventions
- BIOLOGICAL EZN-2279
- BIOLOGICAL Adagen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-01-24 |
| Est. Completion | 2019-05-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01420627
The ClinicalTrials.gov registry entry for NCT01420627 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Leadiant Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EZN-2279 is the first listed.
NCT01420627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01420627 about?
NCT01420627 is a clinical study titled "EZN-2279 in Patients With ADA-SCID". The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.
What is the current status of trial NCT01420627?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2014-01-24. Estimated completion is 2019-05-29.
What interventions are being tested in trial NCT01420627?
The interventions under investigation include: EZN-2279 (BIOLOGICAL), Adagen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01420627?
This trial is sponsored by Leadiant Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.